DK1161250T3 - Immunstimulerende bakteriemembranfraktioner i cancerbehandling - Google Patents

Immunstimulerende bakteriemembranfraktioner i cancerbehandling

Info

Publication number
DK1161250T3
DK1161250T3 DK00910947T DK00910947T DK1161250T3 DK 1161250 T3 DK1161250 T3 DK 1161250T3 DK 00910947 T DK00910947 T DK 00910947T DK 00910947 T DK00910947 T DK 00910947T DK 1161250 T3 DK1161250 T3 DK 1161250T3
Authority
DK
Denmark
Prior art keywords
cancer treatment
membrane fractions
bacterial membrane
preparing
immunostimulatory bacterial
Prior art date
Application number
DK00910947T
Other languages
Danish (da)
English (en)
Inventor
Christine Libon
Alain Beck
Jean-Yves Bonnefoy
Nathalie Corvaia
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of DK1161250T3 publication Critical patent/DK1161250T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK00910947T 1999-03-15 2000-03-15 Immunstimulerende bakteriemembranfraktioner i cancerbehandling DK1161250T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903154A FR2790960B1 (fr) 1999-03-15 1999-03-15 Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
DK1161250T3 true DK1161250T3 (da) 2005-12-12

Family

ID=9543185

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00910947T DK1161250T3 (da) 1999-03-15 2000-03-15 Immunstimulerende bakteriemembranfraktioner i cancerbehandling

Country Status (14)

Country Link
US (1) US7033591B1 (https=)
EP (1) EP1161250B9 (https=)
JP (1) JP2002539170A (https=)
CN (1) CN1202127C (https=)
AT (1) ATE302014T1 (https=)
AU (1) AU776350B2 (https=)
BR (1) BR0009052A (https=)
CA (1) CA2367211A1 (https=)
DE (1) DE60022011T2 (https=)
DK (1) DK1161250T3 (https=)
ES (1) ES2246831T3 (https=)
FR (1) FR2790960B1 (https=)
WO (1) WO2000054790A1 (https=)
ZA (1) ZA200107368B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2808445A1 (fr) * 2000-05-04 2001-11-09 Pf Medicament Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues
FR2809014A1 (fr) * 2000-05-16 2001-11-23 Pf Medicament Utilisation d'une proteine ompa d'enterobacterie comme agent antimicrobien
GB2370838A (en) * 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
FR2822071B1 (fr) * 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
EP4241853B1 (en) * 2013-11-26 2026-02-11 Zoetis Services LLC Compositions for induction of immune response
GB201713975D0 (en) * 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CN113727722A (zh) * 2019-02-22 2021-11-30 伊夫罗生物科学公司 细菌膜制剂
EP4190894A1 (en) 2021-12-03 2023-06-07 CiMaas B.V. Method for the production of mature dendritic cells in vitro using a bacterial lysate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471785A1 (fr) * 1979-12-21 1981-06-26 Fabre Sa Pierre Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn
FR2523154A1 (fr) * 1982-03-09 1983-09-16 Fabre Sa Pierre Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant
FR2596064B1 (fr) * 1986-03-18 1990-02-02 Pf Medicament Procedes industriels de fabrication de vaccins ribosomaux et vaccins ribosomaux obtenus
AU603585B2 (en) * 1986-05-07 1990-11-22 Sloan-Kettering Institute For Cancer Research Vaccine for stimulating or enhancing production of antibodies directed against GM2
AU7477791A (en) * 1990-03-02 1991-09-18 Joaquin J. Jimenez Method for treating cancer using combination chemotherapy and brm
US5242806A (en) * 1990-05-07 1993-09-07 Baxter Diagnostics Inc. Method for conducting the cytotoxicity assays on tumor cells
US5776898A (en) * 1991-05-14 1998-07-07 Dana-Farber Cancer Institute Method for treating a tumor with a chemotherapeutic agent
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
FR2785542B1 (fr) * 1998-11-06 2001-02-09 Pf Medicament UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES

Also Published As

Publication number Publication date
CN1343125A (zh) 2002-04-03
CN1202127C (zh) 2005-05-18
AU3298100A (en) 2000-10-04
EP1161250B1 (fr) 2005-08-17
EP1161250B9 (fr) 2006-07-05
JP2002539170A (ja) 2002-11-19
DE60022011T2 (de) 2006-06-14
FR2790960B1 (fr) 2002-10-31
DE60022011D1 (de) 2005-09-22
BR0009052A (pt) 2001-12-26
US7033591B1 (en) 2006-04-25
ATE302014T1 (de) 2005-09-15
WO2000054790A1 (fr) 2000-09-21
CA2367211A1 (fr) 2000-09-21
FR2790960A1 (fr) 2000-09-22
AU776350B2 (en) 2004-09-02
EP1161250A1 (fr) 2001-12-12
ES2246831T3 (es) 2006-03-01
ZA200107368B (en) 2002-06-26

Similar Documents

Publication Publication Date Title
MX2025003080A (es) Conjugados de il-15, y sus usos
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
ATE439137T1 (de) Behandlung von hämatologischen störungen
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
IL146125A0 (en) Novel quinones as disease therapies
HK1052301A1 (zh) α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
BR9510490B1 (pt) composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
PT1057828E (pt) Suspensoes de trovafloxacina para administracao oral
DK1161250T3 (da) Immunstimulerende bakteriemembranfraktioner i cancerbehandling
NZ542328A (en) Use of immune stimulating complex (ISCOM) particles as an adjuvant for an antigenic composition that comprises live micro organisms
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
ES2164011B1 (es) Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
AU4558201A (en) Taxane anticancer agents
ATE346602T1 (de) Bakterienwandfraktionen mit adjuvansaktivität
AU2003230228A1 (en) Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
MX2022001937A (es) Composicion inmunogenica.
IL150977A (en) Use of protein source for preparation of a nutitional composition for maintaining or improving the synthesis of mucins
WO2002057281A3 (en) Aminoglycosides as antibiotics
IL159469A0 (en) Xenogenic oligo-or/and polyribonucleotides as agents for the treatment of malignant tumours
EP1417968A3 (en) Antitumour compositions containing propolis and resveratrol
BR9806851A (pt) ComposiçÊes farmaceuticas e alimenticias que contêm bactérias de gênero acetobacter